Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Por Konrad, Robert J, Troutt, Jason S, Cao, Guoqing
Publicado em 2011

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

Por Troutt, Jason S., Alborn, William E., Cao, Guoqing, Konrad, Robert J.
Publicado em 2010

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

Por Welder, Greg, Zineh, Issam, Pacanowski, Michael A., Troutt, Jason S., Cao, Guoqing, Konrad, Robert J.
Publicado em 2010

Isolation and characterization of the circulating truncated form of PCSK9

Por Han, Bomie, Eacho, Patrick I., Knierman, Michael D., Troutt, Jason S., Konrad, Robert J., Yu, Xiaohong, Schroeder, Krista M.
Publicado em 2014

Serum Hepcidin Levels Are Associated With Obesity but Not Liver Disease

Por Vuppalanchi, Raj, Troutt, Jason S, Konrad, Robert J., Ghabril, Marwan, Saxena, Romil, Bell, Lauren N, Kowdley, Kris V., Chalasani, Naga
Publicado em 2013